Orgenesis Inc. Appoints Experienced Pubco Development Professional to Board of Directors
WHITE PLAINS, NY -- (Marketwire) -- 04/30/12 -- Orgenesis Inc. (OTCBB: ORGS) ("Orgenesis" or the "Company"), a development stage company with a novel therapeutic technology dedicated to convert a patient's own liver cells into functional insulin-producing cells as a treatment for diabetes, is pleased to announce the appointment of Mr. Yaron Adler to the Company's Board of Directors.
In 1999 Mr. Adler co-founded IncrediMail Ltd. and served as its CEO until February 2008 and as President until May 2009. In January of 2006, Mr. Adler, in participation with MAXIM Investment Banking Group, led the company to a highly successful IPO on the NASDAQ exchange in New York. Mr. Alder is also a director as well as avid investor or advisor with many internet and mobility application companies and startups which notably includes eToro, Typemock, inneractive, Traffilog, Triplay and WhiteSmoke, amongst others. Mr. Adler has enjoyed a lengthy and successful history providing his consulting services to a number of startup companies encompassing a varied mix of products, services and technologies. Mr. Adler served as a Product Manager from 1997 to 1999, and as a software engineer from 1994 to 1997, at Tecnomatix Technologies Ltd. In 1993, Mr. Adler held a software engineer position at Intel Israel. He has a B.A. in computer sciences and economics from Tel-Aviv University.
Company CEO Jacob BenArie comments, "The addition of Yaron brings us access to, and the services of, a highly effective serial entrepreneur and business developer who has successfully led or been instrumental in assisting firms to grow from startup to IPO on a number of public markets and continues to assist many of them currently. He knows what it takes to launch new technologies and businesses into the marketplace and to attract, grow and hold the interest and trust of an investment community. We look forward to his insight and guidance as we move our Company forward."
Orgenesis invites interested readers to visit our website at www.orgenesis.com to find out more about the Company and its goal to bring about the end of diabetes as we now know it.
Further details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information visit: www.orgenesis.com.
About Orgenesis Inc. (OTCBB: ORGS)
Orgenesis is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes as we now know it. For more information visit: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies .which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase, our ability to retain key employees and our ability to finance development or satisfy the rigorous regulatory requirements for new medical procedures. Competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.
On Behalf of the Board
Vered Caplan, Chairperson
Contact: Investor Relations Crescendo Communications, LLC Email: firstname.lastname@example.org Tel: +1-877-560-9060 Web: www.orgenesis.com
Source: Orgenesis Inc.
Released April 30, 2012